A rare case of vulvar extraskeletal myxoid chondrosarcoma: mimics and diagnostic clues

Sofia S. Liou1, Sanaz Memarzadeh2,3,4,5, Sarah M. Dry1, Rondell P. Graham6, Neda A. Moatamed1

How to cite: Liou SS, Memarzadeh S, Dry SM, Graham RP, Moatamed NA. A rare case of vulvar extraskeletal myxoid chondrosarcoma: mimics and diagnostic clues. Autops Case Rep [Internet]. 2021;11:e2021322. https://doi.org/10.4322/acr.2021.322

ABSTRACT

Only 14 cases of extraskeletal myxoid chondrosarcoma (EMC) of the vulva have been documented in the literature. We report a case of a 63-year-old woman with EMC of the vulva confirmed by both EWSR1 and NR4A3 fluorescence in situ hybridization, the latter of which is a more specific probe for this entity. The unusual location of this tumor of prominent myxoid morphology gave rise to a wide differential diagnosis, which necessitated thorough histologic evaluation and confirmatory ancillary testing in the form of immunohistochemistry and cytogenetic studies. This article aims to review extraskeletal myxoid chondrosarcoma of the vulva and various diagnostic clues to help differentiate it from its histologic mimics. This is the fifth case of vulvar EMC in the literature with confirmation of a NR4A3 gene rearrangement.

Keywords
Chondrosarcoma, Extraskeletal Myxoid; vulva; EWSR1; NR4A3; FISH

INTRODUCTION

Malignant mesenchymal tumors of the vulva are exceedingly rare, with sarcomas accounting for only 1% to 2% of vulvar cancers.1 The most common sarcomas of the vulva are leiomyosarcoma, rhabdomyosarcoma, and epithelioid sarcoma. In contrast, only fourteen cases of extraskeletal myxoid chondrosarcoma (EMC) of the vulva have been reported in the literature.2 EMC usually arises in the proximal extremities of adult patients with a 2:1 predilection for males. The median age of onset is in the fifth decade. It is a rare, aggressive sarcoma that has a high local recurrence rate (30-50%) and metastatic potential (often pulmonary).3 Patients are managed with wide local excision and radiation; poor response to chemotherapy has been documented.4

1 University of California Los Angeles (UCLA), David Geffen School of Medicine, Department of Pathology and Laboratory Medicine, Los Angeles, CA, USA
2 University of California Los Angeles (UCLA), David Geffen School of Medicine, Department of Obstetrics and Gynecology, Los Angeles, CA, USA
3 University of California Los Angeles (UCLA), Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Los Angeles, CA, USA
4 University of California Los Angeles (UCLA), Molecular Biology Institute, Los Angeles, CA, USA
5 The VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
6 Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, MN, USA

Copyright © 2021 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Diagnosis of EMC is based on a combination of histopathologic features and ancillary studies. Microscopically, EMC shows a multinodular growth pattern with anastomosing cords of uniform cells surrounded by abundant myxoid matrix. Chondrocytes are notably absent, and there is accumulating evidence that EMC is unrelated to cartilage, but instead is a mesenchymal neoplasm of uncertain differentiation. Rhabdoid features, which are variably present, are associated with adverse clinical outcome. Other poor prognostic factors include old age, large tumor size ($\geq 10$ cm), and proximal location.\textsuperscript{5,6} Necrosis, hemorrhage, and hemosiderosis can be seen. The mitotic rate is usually low. Tumor cells are variably immunoreactive to S100, synaptophysin, and epithelial membrane antigen. They are negative for cytokeratins, desmin, and smooth muscle actin.\textsuperscript{6} CD34 has been reported to be negative in 7 cases of non-vulvar EMCs.\textsuperscript{7} Cytogenetically, EMC is characterized most commonly by the gene fusion \textit{EWSR1-NR4A3}, or \textit{t}(9;22)(q22;q12). This translocation can be detected by break-apart fluorescence in situ hybridization (FISH). Less commonly, the \textit{NR4A3} gene is rearranged with \textit{TAF15}, which appears to follow a more aggressive course.\textsuperscript{8}

**CASE REPORT**

A 63-year-old woman presented with a 3.6 cm solid mass in the right anterior perineum. The patient first noticed the lesion three years prior as a painless papule on the right vulva. The lesion persisted and gradually grew in size, now causing some pain when lying on the right side. Pre-operative magnetic resonance imaging of the pelvis showed a heterogeneously and avidly enhancing, T2 hyperintense, circumscribed mass in the right labia majora measuring 3.6 x 2.7 cm. The mass was noted to have multiple internal septations and extensive surrounding vascularity. While the mass abutted and exerted mild mass effect on the right adductor musculature, there was no frank invasion into the muscles or adjacent pelvic structures. There was no lymphadenopathy. A computed tomography-guided biopsy was performed which showed a low-grade vascular tumor with myxoid stroma, most consistent with “angiomyofibroblastoma.” Complete excision of the lesion was recommended at this time. Pelvic exam under anesthesia revealed a 4 x 3 cm mass in the right labia majora. A radical wide local excision of this mass was performed which resulted in resection of the entire lesion. The patient did well and had an uneventful postoperative course.

Gross evaluation of the right vulvar lesion showed an irregular soft tissue fragment measuring 4.2 x 3.5 x 2.3 cm. Cut surfaces were tan-red and focally firm. Histopathology showed a spindle cell lesion with hypocellular and hypercellular areas, prominent myxoid stroma, and an overall lobulated architecture with increased cellularity at the periphery of the lobules. The cells, which were characterized by eccentrically placed round to ovoid nuclei with uniformly dispersed chromatin and eosinophilic to vacuolated cytoplasm, were arranged in clusters, trabeculae, and cords. Necrosis and mitotic activity were not seen. The tumor cells appeared low-grade and uniform without appreciable nuclear pleomorphism. The background contained abundant thin-walled vessels and extravasated red blood cells. Tumor was noted to focally infiltrate the surrounding fibrofatty tissue and was present at the inked surgical resection surface (Figures 1A-1C).

The tumor cells were strongly and diffusely positive for CD34 by immunohistochemistry (Figure 1D).

Tumor cells were negative for cytokeratin, epithelial membrane antigen (EMA), smooth muscle actin (SMA), desmin, caldesmon, estrogen receptor, and S100. INI1 (SMARCB1) expression was retained. \textit{EWSR1} FISH was performed and was positive for \textit{EWSR1} rearrangement, consistent with a diagnosis of extraskeletal myxoid chondrosarcoma (Figure 2A). However, because \textit{EWSR1} rearrangement can also be seen in a number of soft tissue sarcomas,\textsuperscript{7} confirmatory \textit{NR4A3} FISH was performed. Positive \textit{NR4A3} gene rearrangement by FISH was further supportive of extraskeletal myxoid chondrosarcoma (Figure 2B). Also, molecular biomarker findings at Foundation-One-Heme (Cambridge, MA, USA) included \textit{ESWR1-NR4A3} fusion and stable microsatellite status.

Post-operative imaging of the chest, abdomen, and pelvis showed post-surgical changes with no evidence of metastatic disease. The patient was referred to a sarcoma specialist with post-operative management to include a 6-week course of radiation and surveillance.
The differential diagnosis of myxoid vulvar lesions is broad, as a significant degree of morphologic, immunophenotypic, and even molecular overlap exists among these entities. These overlapping diagnostic features make accurate diagnosis challenging, particularly on small biopsy specimens where sampling of the lesion is limited. What follows is a discussion of histologic mimics of EMC, with a focus on angiomyofibroblastoma, aggressive angiomyxoma, myxofibrosarcoma, myoepithelial carcinoma, and myoepithelial-like tumors of the vulvar region.

Angiomyofibroblastoma, a benign vulvar tumor with low rates of local recurrence, was initially favored on our biopsy specimen based on morphologic features. Angiomyofibroblastoma is characterized by alternating hypercellular and hypocellular areas admixed with small blood vessels. The stromal cells are spindled and plump, characteristically arranged around the vasculature and often present in clusters. Lesional cells are immunoreactive to desmin and vimentin, but usually negative for cytokeratin and smooth muscle actin. While our biopsy sample had similar histopathologic and immunophenotypic features, with the addition of CD34 immunoreactivity,

**DISCUSSION**

![Figure 1. Histopathology and Immunohistochemistry. A – Low power photomicrograph of a hematoxylin and eosin stain shows the nodular architecture of the tumor with hypercellular and hypocellular regions with increased cellularity at the periphery of the lobules. The right side of the image shows pale blue myxoid matrix representing hypocellular areas. The left side, more eosinophilic appearing, shows both organoid and lobular growth patterns (2x objective); B – Abundant myxoid stroma with uniform cells arranged in trabeculae and interconnecting cords (20x objective); C – Rhabdoid cells with eccentrically located nuclei and eosinophilic to finely vacuolated cytoplasm (40x objective); D – CD34 immunohistochemical stain depicts tumor cells with intense cell membrane staining (20x objective).](image-url)
the excisional specimen lacked prominent aggregation of neoplastic cells around the vasculature. In addition, the histologically multinodular architecture of the excision specimen lowered angiomyofibroblastoma on the differential.  

Aggressive angiomyxoma is another entity that can be confused with EMC of the vulva, due to its prominent vasculature and hypocellular stroma on microscopy, as well as its much more frequent occurrence in the perineum. Aggressive angiomyxoma often presents as a large vulvar mass with a gross appearance that is ill-defined and edematous. Morphologically, the tumor consists of hypocellular stroma without atypical cells or mitotic activity, admixed with medium- to large-sized vessels with dilated lumina and occasional adventitial thickening. The tumor is often large and deep-seated with infiltrative borders, compared to its more superficial counterpart, superficial angiomyxoma, which is frequently exophytic and well-circumscribed. The cells of aggressive angiomyxoma are immunoreactive to desmin, smooth muscle actin (about half), CD34 (about half), and estrogen and progesterone receptors. While aggressive angiomyxoma entered our differential, our lesion was more cellular and had smaller vessels rather than the large- to medium-sized vessels frequently described. Furthermore, while angiomyxomas often show an edematous stroma, diffuse myxoid stroma, as seen in this case, is not typical. In addition, our lesion was immunophenotypically inconsistent given the negative staining for desmin, smooth muscle actin, and estrogen receptor.

Myxofibrosarcoma is another entity showing morphologic overlap with EMC. Myxofibrosarcoma is
a more common sarcoma than EMC, and it is often found in the subcutaneous tissues of the extremities of elderly individuals. The classic morphology shows a hypocellular myxoid tumor with numerous prominent curvilinear blood vessels and lesional spindle cells that show at least focal moderate to marked pleomorphism with hyperchromatic nuclei. The lesion tends to be multinodular with infiltrative borders. Lesional cells can be immunoreactive to smooth muscle actin and CD34, but not always. They are negative for cytokeratin and desmin.\textsuperscript{11} In our case, the relatively uniform nuclei, architectural arrangements of cells in clusters, trabeculae and cords in addition to epithelioid and rhabdoid morphology favored EMC over myxofibrosarcoma.

Myoepithelial carcinoma is an important diagnostic consideration as well. Myoepithelial carcinomas in the soft tissue are analogous to their salivary gland counterpart. Not only do they have highly variable morphology with features overlapping with EMC, almost 50\% of soft tissue myoepithelial carcinomas harbor an EWSR1 gene rearrangement as well.\textsuperscript{12} Fortunately, NR4A3 rearrangement has been negative in all cases of myoepithelial carcinoma reported in the literature to date. Thus, NR4A3 FISH can be used to distinguish between EMC and myoepithelial carcinoma when morphologic features are inconclusive and EWSR1 gene rearrangement is present. Immunohistochemistry can also be helpful: myoepithelial carcinomas express myoepithelial markers like p63, S100, glial fibrillary acidic protein (GFAP), and EMA, but these are not expressed in EMC.\textsuperscript{13}

While the morphologic features of extraskeletal myxoid chondrosarcoma can conjure a wide differential, histologic clues and ancillary testing can help resolve diagnostic dilemmas. Of note, our case was strongly positive with CD34, which has not been previously reported in EMcs. Cytogenetic studies are particularly useful here, as EWSR1-NR4A3 fusions are seen in roughly 75\% of cases of EMC.\textsuperscript{14} EWSR1 FISH is more widely available and thus can be useful as the initial diagnostic probe of choice. NR4A3 has fewer fusion partners than EWSR1 and therefore can be used as a confirmatory probe with higher specificity.\textsuperscript{14} So far, we have identified only 4 cases of rearranged-NR4A3 cases of vulvar EMC in the literature, making our cases the fifth report. Noguchi et al.\textsuperscript{14} and Flucke et al.\textsuperscript{15} each had two cases of vulvar EMC with confirmatory NR4A3 rearrangement by fluorescence in situ hybridization.

**CONCLUSION**

Extraskeletal myxoid chondrosarcoma of the vulva is an uncommon diagnosis in an unusual location. In addition to its rarity, the diagnosis of EMC can be challenging because of overlapping morphologic and immunophenotypic features with other myxoid mesenchymal neoplasms. Moreover, distinguishing morphologic features that are seen in excisional specimens may not be seen initially on small biopsy specimens. Representative tumor sampling thus cannot be overlooked. Cytogenetic and/or molecular studies are particularly useful for an accurate diagnosis of EMC. EWSR1 and particularly NR4A3 FISH analyses can help narrow this difficult differential. For the EWSR1-NR4A3 fusion, there is a targeted treatment available. Pazopanib has been reported to have anti-tumor activity in patients with progressive and advanced EMC.\textsuperscript{16} As our case illustrates, thorough morphologic evaluation and ancillary testing, in conjunction with imaging and clinical correlation, necessarily precede an accurate diagnosis of extraskeletal myxoid chondrosarcoma of the vulva.

**REFERENCES**

1. O’Neill D, Elghobashy M, Abdelsalam H, Metelko M, El-Ghobashy A. A 5-year follow-up of vulval swelling due to extraskeletal myxoid chondrosarcoma: a rare case report. Mol Clin Oncol. 2019;10(5):483-6. http://dx.doi.org/10.3892/mco.2019.1822. PMid:30967942.
2. Salah HT, Stivers NS, Jarboe EA, Dodson MK, Ward MB. Extraskeletal myxoid chondrosarcoma of the vulva confirmed by EWSR1 FISH: a case report and review of the literature. Int J Gynecol Pathol. 2020. [Publish ahead of print]. http://dx.doi.org/10.1097/ PGP.0000000000000723. PMid:33075019.
3. Stacchiotti S, Baldi GG, Morosi C, Gronchi A, Maestro R. Extraskeletal myxoid chondrosarcoma: state of the art and current research on biology and clinical management. Cancers. 2020;12(9):2703. http://dx.doi.org/10.3390/ cancers12092703. PMid:32967265.
4. Stacchiotti S, Dagrada GP, Morosi C, et al. Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. Clin Sarcoma Res. 2012;2(1):22. http://dx.doi. org/10.1186/2045-3329-2-22. PMid:23058004.
A rare case of vulvar extraskeletal myxoid chondrosarcoma: mimics and diagnostic clues

5. Oliveira AM, Sebo TJ, McGrory JE, Gaffey TA, Rock MG, Nascimento AG. Extraskeletal myxoid chondrosarcoma: a clinicopathologic, immunohistochemical, and ploidy analysis of 23 cases. Mod Pathol. 2000;13(8):900-8. http://dx.doi.org/10.1038/modpathol.3880161. PMid:10955458.

6. Horvai AE, Lucas DR, Agaram NP. Extraskeletal myxoid chondrosarcoma. In: Antonescu CR, Blay JY, Bovée JVMG, et al., editors. Soft tissue and bone tumours. WHO Classification of Tumours. 5th ed. Lyon: IARC; 2020. p. 303-5.

7. Huang H, Chen X, Zheng Z. Extraskeletal myxoid chondrosarcoma: a clinicopathologic analysis of seven cases. Zhonghua Bing Li Xue Za Zhi. 2016;45(1):25-30. PMid:26791550.

8. Brenca M, Stacchiotti S, Fassetta K, et al. NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas. J Pathol. 2019;249(1):90-101. http://dx.doi.org/10.1002/path.5284. PMid:31020999.

9. Fletcher CDM. Angiomyofibroblastoma. In: Antonescu CR, Blay JY, Bovée JVMG, et al., editors. Soft tissue and bone tumours. WHO Classification of Tumours. 5th ed. Lyon: IARC; 2020. p. 78-9.

10. Nucci MR, Julia A, Bridge JA. Deep (aggressive) angiomyxoma. In: Antonescu CR, Blay JY, Bovée JVMG, et al., editors. Soft tissue and bone tumours. WHO Classification of Tumours. 5th ed. Lyon: IARC; 2020. p. 266-7.

11. Huang HY, Mentzel TDW, Shibata T. Myxofibrosarcoma. In: Antonescu CR, Blay JY, Bovée JVMG, et al., editors. Soft tissue and bone tumours. WHO Classification of Tumours. 5th ed. Lyon: IARC; 2020. p. 124-6.

12. Antonescu CR, Zhang L, Chang NE, et al. EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosomes Cancer. 2010;49(12):1114-24. http://dx.doi.org/10.1002/gcc.20819. PMid:20815032.

13. Jo VY, Hornick JL, Antonescu CR, Patel RM. Myoepithelioma, myoepithelial carcinoma, and mixed tumour. In: Antonescu CR, Blay JY, Bovée JVMG, et al., editors. Soft tissue and bone tumours. WHO Classification of Tumours. 5th ed. Lyon: IARC; 2020. p. 277-9.

14. Noguchi H, Mitsusashi T, Seki K, et al. Fluorescence in situ hybridization analysis of extraskeletal myxoid chondrosarcomas using EWSR1 and NR4A3 probes. Hum Pathol. 2010;41(3):336-42. http://dx.doi.org/10.1016/j.humpath.2009.04.028. PMid:19775727.

15. Flucke U, Tops BB, Verdijk MA, et al. NR4A3 rearrangement reliably distinguishes between the clinicopathologically overlapping entities myoepithelial carcinoma of soft tissue and cellular extraskeletal myxoid chondrosarcoma. Virchows Arch. 2012;460(6):621-8. http://dx.doi.org/10.1007/s00428-012-1240-0. PMid:22569967.

16. Stacchiotti S, Ferrari S, Redondo A, et al. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2019;20(9):1252-62. http://dx.doi.org/10.1016/S1470-2045(19)30319-5. PMid:31331701.

This study was carried out at David Geffen School of Medicine at UCLA. Los Angeles, CA, USA.

**Authors’ contributions:** Sofia Shiao-Huei Liou beside being involved in handling the case, she reviewed and wrote the initial draft. Sanaz Memarzadeh has performed the surgery and clinical follow-ups of the patient and provided the related texts. Sarah Margaret Dry was involved in making the initial diagnosis and reviewing the manuscript. Rondell Patrell Graham was responsible for the EWSR1-NR4A3 cytogenetic studies. Neda Aliyari Moatamed signed out the pathology report, reviewed the case from the beginning, and made the final review and edited the manuscript including the figures section and formatting. All authors have reviewed and approved the final version of this manuscript.

Ethics Statement: The IRB at UCLA does not require approval for case reports if all identifying references are removed, and the patient has not been a subject of human studies which has been the case in this report.

**Conflict of interest:** The authors have no conflict of interest to declare.

**Financial support:** Sanaz Memarzadeh is supported by a Department of Veterans Affairs Merit Award, grant number I01BX004651.

**Submitted on:** June 15th, 2021

**Accepted on:** July 11th, 2021
Correspondence
Neda Aliyari Moatamed
University of California Los Angeles (UCLA), David Geffen School of Medicine, Department of Pathology and Laboratory Medicine
10833, Le Conte Avenue, BOX 951732, 13-145 CHS, 90095-1732, Los Angeles, CA, USA
Phone: +1 (310) 825-0581
nmoatamed@mednet.ucla.edu